Sandoz launches generic Angiomax through Medicines Company partnership

PRINCETON, N.J. — Sandoz has launched its generic version of Angiomax (bivalirudin), an anticoagulant injection. The drug’s U.S. launch is the result of a supply and distribution agreement with the Medicines Company.

“This agreement with The Medicines Company for an authorized generic bivalirudin reflects our commitment to making high-quality generic injectables available to patients and healthcare professionals in the U.S.,”  Sandoz President Peter Goldschmidt said.

Bivalirudin is an anticoagulant indicated for patients with unstable angina undergoing coronary angioplasty, as well as those undergoing percutaneous coronary intervention or those with heparin-induced thrombocytopenia, among other indications. IMS Health projected that in the 12 months ending in April 2015, the brand-name treatment sales were about $485 million.